MX2022016197A - Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos. - Google Patents

Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos.

Info

Publication number
MX2022016197A
MX2022016197A MX2022016197A MX2022016197A MX2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A MX 2022016197 A MX2022016197 A MX 2022016197A
Authority
MX
Mexico
Prior art keywords
antibodies
antibody fragments
immunoconjugates
chain variable
variable region
Prior art date
Application number
MX2022016197A
Other languages
English (en)
Spanish (es)
Inventor
Gerhard Frey
Hwai Wen Chang
Jay M Short
Jing Wang
Chao Xing
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of MX2022016197A publication Critical patent/MX2022016197A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
MX2022016197A 2020-06-18 2021-06-15 Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos. MX2022016197A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040913P 2020-06-18 2020-06-18
PCT/US2021/037400 WO2021257542A1 (en) 2020-06-18 2021-06-15 Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016197A true MX2022016197A (es) 2023-04-05

Family

ID=79268294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016197A MX2022016197A (es) 2020-06-18 2021-06-15 Anticuerpos anti-cd46 condicionalmente activos, fragmentos de anticuerpo, sus inmunoconjugados y sus usos.

Country Status (11)

Country Link
US (1) US20230242662A1 (https=)
EP (1) EP4168452A4 (https=)
JP (2) JP7795206B2 (https=)
KR (1) KR20230023800A (https=)
CN (1) CN115702167A (https=)
AU (1) AU2021292486A1 (https=)
CA (1) CA3182384A1 (https=)
IL (1) IL298902A (https=)
MX (1) MX2022016197A (https=)
TW (1) TWI906314B (https=)
WO (1) WO2021257542A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2810016A1 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
CN107135654B (zh) * 2014-09-12 2021-10-29 加利福尼亚大学董事会 巨胞饮人类抗cd46抗体和靶向癌症疗法
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2017078839A1 (en) * 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
KR102873209B1 (ko) * 2016-08-31 2025-10-17 바이오아트라, 인코퍼레이티드 조건부 활성 폴리펩티드 및 이를 제조하는 방법
ES3005158T3 (en) * 2016-11-11 2025-03-14 Univ California Anti-cd46 antibodies and methods of use
CN109535260B (zh) * 2018-11-22 2021-08-10 东南大学 一种靶向cd46的人源嵌合抗原受体及其应用

Also Published As

Publication number Publication date
JP2026053430A (ja) 2026-03-25
KR20230023800A (ko) 2023-02-17
IL298902A (en) 2023-02-01
TWI906314B (zh) 2025-12-01
CN115702167A (zh) 2023-02-14
JP2023531189A (ja) 2023-07-21
WO2021257542A1 (en) 2021-12-23
EP4168452A1 (en) 2023-04-26
AU2021292486A1 (en) 2023-02-09
TW202214696A (zh) 2022-04-16
EP4168452A4 (en) 2024-07-10
JP7795206B2 (ja) 2026-01-07
CA3182384A1 (en) 2021-12-23
US20230242662A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
MX2022016192A (es) Anticuerpos anti-nectina-4 condicionalmente activos.
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MY205933A (en) Sirp-alpha binding proteins and methods of use thereof
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
EA202190542A1 (ru) Сконструированные биспецифические белки
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
TN2010000197A1 (en) New antibodies specific of the beta -amyloid peptides and their uses as diagnostic agents or drugs
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
EA201991912A1 (ru) Составы, содержащие pd-1-связывающие белки, и способы их получения
ZA202203460B (en) Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap)
SG10201801219VA (en) Anti-HER2 Antibodies
EA202092420A1 (ru) Антитело против pd-l1 и его применение